Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action
Open Access
- 8 December 2017
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (5) , 5979-5992
Abstract
Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor actionKeywords
This publication has 56 references indexed in Scilit:
- Hydroquinone regulates hemeoxygenase-1 expression via modulation of Src kinase activity through thiolation of cysteine residuesFree Radical Biology and Medicine, 2013
- Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3Cancer Cell, 2011
- Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studiesCancer Letters, 2010
- The Role of Src in Solid TumorsThe Oncologist, 2009
- Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemiaLeukemia & Lymphoma, 2008
- The role of Src in prostate cancerAnnals of Oncology, 2007
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: Crystal structures of the complexed and peptide-free formsCell, 1993
- Studies on the role of basic fibroblast growth factor in vivo: Inability of neutralizing antibodies to block tumor growthJournal of Cellular Physiology, 1990